Term ends Nov 25, 2028 · High confidence
20-year base term ends Nov 25, 2028
Held by Vitaeris Inc.
Filed Nov 25, 2008 as application 12/323,066 · Granted Mar 26, 2013
Base term, 20 years from filing
Today
2008
2028
Clock starts
Nov 25, 2008
Nov 25, 2008
Term ends
Nov 25, 2028
Nov 25, 2028
Granted
Mar 26, 2013
Mar 26, 2013
base term
fee events
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 8,420,089, US 8,535,671, to Nov 25, 2028. The term already ends on or before that date, so the cap shortened nothing.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
65
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. All three maintenance fees are recorded paid; no more fees are due. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Nov 25, 2008, when this application, 12/323,066, was filed | Nov 25, 2028 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 8,420,089, US 8,535,671) | resolves to Nov 25, 2028, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Nov 25, 2028 | High confidence |
This family
| Application 12/124,723 | Abandoned not computed | not computed |
| US 9,056,905 | Lapsed on the fee record Jun 2023 | Jun 2023 |
| US 7,935,340 | In force May 2028 | May 2028 |
| US 8,404,235 | this patent Nov 2028 | Nov 2028 |
| US 7,906,117 | In force Nov 2028 | Nov 2028 |
| US 8,252,286 | In force May 2028 | May 2028 |
| Application 61/117,839 | Provisional application no patent term | no patent term |
| Application 61/117,811 | Provisional application no patent term | no patent term |
8 of 65 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Feb 17, 2009 Reel 22264, frame 501 | Smith, Jeffrey T.l. | Alder Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Jan 4, 2011 Reel 25577, frame 826 | Alder Biopharmaceuticals, Inc. | Alderbio Holdings LLC | Assignment of Assignor's Interest |
| Jan 5, 2011 Reel 25587, frame 523 | Alderbio Holdings LLC | Bristol-Myers Squibb Company | Assignment of Assignor's Interest |
| Jan 24, 2011 Reel 25681, frame 634 | Alderbio Holdings Inc. | Bristol-Myers Squibb Company | Corrective Assignment to Correct the Assignment of Assignee's Interest in Non-US Cases Only for Assignment Previously Recorded on Reel 025587 Frame 0523. Assignor(S) Hereby Confirms the Conveyance of Non-US Rights of Patents Relating to Applications Listed in Assignment. Prior PP. 1-2 Were Filed in Error. |
| Nov 28, 2012 Reel 29372, frame 56 | Alderbio Holdings LLC | Bristol-Myers Squibb Company | Corrective Assignment to Correct the Assignee's Name in Non-US Cases Only Previously Recorded on Reel 025681 Frame 0634. Assignor(S) Hereby Confirms the Conveyance of Non-US Rights of Patents Relating to Applications Listed in Assignment.. |
| Feb 5, 2014 Reel 32161, frame 853 | Smith, Jeffrey T.l. | Alder Biopharmaceuticals, Inc. | Corrective Assignment to Correct the Assignee's Name to Correctly Read Alder Biopharmaceuticals, Inc. Previously Recorded on Reel 022264 Frame 0501. Assignor(S) Hereby Confirms the Assignment of Assignors' Interest. |
| Feb 24, 2014 Reel 32329, frame 931 | Bristol-Myers Squibb Company | Alderbio Holdings LLC | Assignment of Assignor's Interest |
| Feb 25, 2014 Reel 32332, frame 787 | Alderbio Holdings LLC | Bristol-Myers Squibb Company | Assignment of 1/2 Interest in Non-U.S. Applications |
| Dec 12, 2014 Reel 34491, frame 663 | Bristol-Myers Squibb Company | Alderbio Holdings LLC | Assignment of Assignor's Interest |
| Jan 16, 2015 Reel 34777, frame 728 | Bristol-Myers Squibb Company | Alderbio Holdings LLC | Assignment of Assignor's Interest |
| Jun 23, 2020 Reel 53020, frame 143 | Alder Biopharmaceuticals, Inc. | Lundbeck Seattle Biopharmaceuticals, Inc. | Change of Name |
| Jun 23, 2020 Reel 53020, frame 205 | Lundbeck Seattle Biopharmaceuticals, Inc. | H. Lundbeck A/S | Assignment of Assignor's Interest |
| Aug 14, 2020 Reel 53496, frame 319 | H. Lundbeck A/S | Vitaeris Inc. | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Nov 2028
Term ends Nov 25, 2028. No further fees fall due before then
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 8,420,089, US 8,535,671, ends no earlier than this term, so it caps nothing.
Citations
56
later US patents cite this one
That is top 10% of utility patents granted in 2013 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.